Recently, an irreversible covalent inhibitor against K-Ras(G12C), a mutation detected mainly in lung cancer, was granted regulatory approval based on clinical trial data showing efficacy as monotherapy2,3. This evidence concerns the gene KRAS and lung carcinoma.